Legacy CG LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Legacy CG LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 6,995 shares of the company's stock, valued at approximately $5,777,000. Eli Lilly and Company accounts for approximately 1.9% of Legacy CG LLC's holdings, making the stock its 21st biggest holding.

Several other institutional investors also recently modified their holdings of the stock. Artemis Investment Management LLP grew its position in shares of Eli Lilly and Company by 24.5% during the 1st quarter. Artemis Investment Management LLP now owns 75,068 shares of the company's stock worth $61,999,000 after buying an additional 14,758 shares during the period. Transcend Capital Advisors LLC grew its position in shares of Eli Lilly and Company by 4.1% during the 1st quarter. Transcend Capital Advisors LLC now owns 18,038 shares of the company's stock worth $14,898,000 after buying an additional 703 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its position in shares of Eli Lilly and Company by 2.2% during the 1st quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 10,070 shares of the company's stock worth $8,352,000 after buying an additional 215 shares during the period. Diversified Trust Co grew its position in shares of Eli Lilly and Company by 13.3% during the 1st quarter. Diversified Trust Co now owns 16,615 shares of the company's stock worth $13,723,000 after buying an additional 1,955 shares during the period. Finally, Beacon Financial Advisory LLC grew its position in shares of Eli Lilly and Company by 32.9% during the 1st quarter. Beacon Financial Advisory LLC now owns 372 shares of the company's stock worth $307,000 after buying an additional 92 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 2.4%

Shares of LLY stock traded down $18.94 on Friday, hitting $776.18. The company had a trading volume of 4,109,419 shares, compared to its average volume of 3,683,590. The firm has a market cap of $735.61 billion, a P/E ratio of 63.16, a P/E/G ratio of 1.13 and a beta of 0.40. The stock's 50-day moving average is $780.19 and its two-hundred day moving average is $799.96. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the company posted $2.58 EPS. The company's quarterly revenue was up 45.2% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.77%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. Finally, Wall Street Zen lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.